Company profile: Precision Biologics
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutic and diagnostic products for the early detection and treatment of cancer, including monoclonal antibody drug candidates NEO-201 and Ensituximab (NEO-102), companion diagnostics (IHC and serum ELISA) to predict and monitor patient response, and clinical trials evaluating the efficacy of their therapeutic antibodies.
Products and services
- Companion Diagnostics: Precision Biologics delivers assay-based tests, including IHC and serum ELISA, to predict response to antibody therapy, enabling cancer detection and longitudinal monitoring in clinical patients
- Ensituximab (NEO-102): Precision Biologics engineers a monoclonal antibody for pancreatic and colorectal adenocarcinoma, with a Phase 2 trial completed in metastatic colorectal cancer to target tumors while sparing healthy cells
- NEO-201: Precision Biologics develops a monoclonal antibody targeting truncated Core‑1 O‑glycan, exhibiting efficacy in preclinical and patient studies against multiple tumor types and designed to spare non‑malignant cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Precision Biologics
U-Systems
HQ: United States
Website
- Description: Provider of automated breast ultrasound systems and software that deliver automated breast scans to assist radiologists in detecting breast cancer, particularly in women with dense breast tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U-Systems company profile →
Epigenomics
HQ: Germany
Website
- Description: Provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epigenomics company profile →
Galil Medical
HQ: United States
Website
- Description: Provider of minimally invasive cryotherapy technology and systems for various clinical applications, using compressed Argon gas to freeze and ablate diseased tissue in procedures referred to as cryotherapy, cryoablation, or cryosurgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galil Medical company profile →
Zionexa
HQ: United States
Website
- Description: Provider of in-vivo biomarkers developed and commercialized to guide targeted therapies in oncology, aiming to improve patients' pathway and quality of life.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zionexa company profile →
Delphinus Medical
HQ: United States
Website
- Description: Provider of breast cancer screening solutions for hospitals and imaging clinics, developing, commercializing, and servicing the SoftVue 3D Whole Breast Ultrasound Tomography, a 3D whole breast ultrasound system for dense breast screening that increases cancer detection by 20% when used alongside mammography.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delphinus Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Precision Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Precision Biologics
2.2 - Growth funds investing in similar companies to Precision Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Precision Biologics
4.2 - Public trading comparable groups for Precision Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →